MedTrace Logo

Evaluating the Role of Pre-existing Resolvins in the Resolution of ICU Delirium

NCT04575753 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-03-30

No results posted yet for this study

Summary

As patient management is improving, more and more ICU survivors are being confronted with cognitive dysfunction and this well after their hospital stay.

In the ICU, delirium rates have been reported to be as high at 81%. Delirium is associated with patient and family stress, increased hospital costs, increased duration of stay, escalation of care and increased mortality and morbidity.

The physiopathology of ICU cognitive impairment is complex and involves an inflammatory cascade Recently, the role of 'resolvins' derived from omega-3 fatty acids has been studied in the resolution of inflammation.

Therefore, this hypothesis of this study is that ICU patients with higher serum levels of resolvins at ICU admission, ICU day 2 and day 5 will have a lesser degree of cognitive impairment on day 5 of ICU stay.

Conditions

  • Delirium

Interventions

OTHER

Study group

Blood samples will be taken from ICU patients on the day of ICU admission, day 2 and day 5 after ICU admission. Similarly, patients will be subjected to cognitive testing (CAM-ICU) to determine the presence of delirium

Sponsors & Collaborators

  • CHU de Charleroi

    collaborator OTHER

  • Université Libre de Bruxelles

    lead OTHER

Principal Investigators

  • Michael Piagnerelli, MD; PHD · CHU de Charleroi, Belgium

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-07
Primary Completion
2024-05-30
Completion
2024-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04575753 on ClinicalTrials.gov